pre-IPO PHARMA

COMPANY OVERVIEW

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 53,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://www.boehringer-ingelheim.com/


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Sep 14, 2023

Boehringer Ingelheim receives SBTi validation for CO2 reduction targets


Aug 1, 2023

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas


Jun 23, 2023

Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)1


May 10, 2023

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight


May 9, 2023

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases


For More Press Releases


Google Analytics Alternative